Literature DB >> 28483946

p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.

Kyrie Pappas1,2,3, Jia Xu1,2, Sakellarios Zairis4, Lois Resnick-Silverman1,2, Francesco Abate4,5, Nicole Steinbach1,2,6, Sait Ozturk1,2, Lao H Saal7,8,9, Tao Su10, Pamela Cheung1,2, Hank Schmidt2,11,12, Stuart Aaronson1,2, Hanina Hibshoosh10, James Manfredi1,2, Raul Rabadan4,5, Ramon Parsons13,2.   

Abstract

TP53 is the most commonly mutated tumor suppressor gene and its mutation drives tumorigenesis. Using ChIP-seq for p53 in the absence of acute cell stress, we found that wild-type but not mutant p53 binds and activates numerous tumor suppressor genes, including PTEN, STK11(LKB1), miR-34a, KDM6A(UTX), FOXO1, PHLDA3, and TNFRSF10B through consensus binding sites in enhancers and promoters. Depletion of p53 reduced expression of these target genes, and analysis across 18 tumor types showed that mutation of TP53 associated with reduced expression of many of these genes. Regarding PTEN, p53 activated expression of a luciferase reporter gene containing the p53-consensus site in the PTEN enhancer, and homozygous deletion of this region in cells decreased PTEN expression and increased growth and transformation. These findings show that p53 maintains expression of a team of tumor suppressor genes that may together with the stress-induced targets mediate the ability of p53 to suppress cancer development. p53 mutations selected during tumor initiation and progression, thus, inactivate multiple tumor suppressor genes in parallel, which could account for the high frequency of p53 mutations in cancer.Implications: In this study, we investigate the activities of p53 under normal low-stress conditions and discover that p53 is capable of maintaining the expression of a group of important tumor suppressor genes at baseline, many of which are haploinsufficient, which could contribute to p53-mediated tumor suppression. Mol Cancer Res; 15(8); 1051-62. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28483946      PMCID: PMC5587155          DOI: 10.1158/1541-7786.MCR-17-0089

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene.

Authors:  G S Wu; T F Burns; E R McDonald; W Jiang; R Meng; I D Krantz; G Kao; D D Gan; J Y Zhou; R Muschel; S R Hamilton; N B Spinner; S Markowitz; G Wu; W S el-Deiry
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

Review 2.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

3.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

4.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

5.  Subtle variations in Pten dose determine cancer susceptibility.

Authors:  Andrea Alimonti; Arkaitz Carracedo; John G Clohessy; Lloyd C Trotman; Caterina Nardella; Ainara Egia; Leonardo Salmena; Katia Sampieri; William J Haveman; Edi Brogi; Andrea L Richardson; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

6.  A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping.

Authors:  Suhas S P Rao; Miriam H Huntley; Neva C Durand; Elena K Stamenova; Ivan D Bochkov; James T Robinson; Adrian L Sanborn; Ido Machol; Arina D Omer; Eric S Lander; Erez Lieberman Aiden
Journal:  Cell       Date:  2014-12-11       Impact factor: 41.582

7.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Authors:  Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo A Ferrando; Per Malmström; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

8.  LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.

Authors:  Jennifer P Morton; Nigel B Jamieson; Saadia A Karim; Dimitris Athineos; Rachel A Ridgway; Colin Nixon; Colin J McKay; Ross Carter; Valerie G Brunton; Margaret C Frame; Alan Ashworth; Karin A Oien; T R Jeffry Evans; Owen J Sansom
Journal:  Gastroenterology       Date:  2010-05-06       Impact factor: 22.682

9.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

10.  BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells.

Authors:  Huifeng Niu; Giorgio Cattoretti; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2003-07-14       Impact factor: 14.307

View more
  19 in total

1.  NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity.

Authors:  Nasir Haider; Previn Dutt; Bert van de Kooij; Jason Ho; Luis Palomero; Miquel Angel Pujana; Michael Yaffe; Vuk Stambolic
Journal:  Oncogene       Date:  2020-06-19       Impact factor: 9.867

2.  Proteogenomic Characterization of Endometrial Carcinoma.

Authors:  Yongchao Dou; Emily A Kawaler; Daniel Cui Zhou; Marina A Gritsenko; Chen Huang; Lili Blumenberg; Alla Karpova; Vladislav A Petyuk; Sara R Savage; Shankha Satpathy; Wenke Liu; Yige Wu; Chia-Feng Tsai; Bo Wen; Zhi Li; Song Cao; Jamie Moon; Zhiao Shi; MacIntosh Cornwell; Matthew A Wyczalkowski; Rosalie K Chu; Suhas Vasaikar; Hua Zhou; Qingsong Gao; Ronald J Moore; Kai Li; Sunantha Sethuraman; Matthew E Monroe; Rui Zhao; David Heiman; Karsten Krug; Karl Clauser; Ramani Kothadia; Yosef Maruvka; Alexander R Pico; Amanda E Oliphant; Emily L Hoskins; Samuel L Pugh; Sean J I Beecroft; David W Adams; Jonathan C Jarman; Andy Kong; Hui-Yin Chang; Boris Reva; Yuxing Liao; Dmitry Rykunov; Antonio Colaprico; Xi Steven Chen; Andrzej Czekański; Marcin Jędryka; Rafał Matkowski; Maciej Wiznerowicz; Tara Hiltke; Emily Boja; Christopher R Kinsinger; Mehdi Mesri; Ana I Robles; Henry Rodriguez; David Mutch; Katherine Fuh; Matthew J Ellis; Deborah DeLair; Mathangi Thiagarajan; D R Mani; Gad Getz; Michael Noble; Alexey I Nesvizhskii; Pei Wang; Matthew L Anderson; Douglas A Levine; Richard D Smith; Samuel H Payne; Kelly V Ruggles; Karin D Rodland; Li Ding; Bing Zhang; Tao Liu; David Fenyö
Journal:  Cell       Date:  2020-02-13       Impact factor: 41.582

3.  A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia.

Authors:  Olga Lancho; Jui-Wan Loh; Amartya Singh; Shunsuke Kimura; Luca Tottone; Juliette Roels; Anna Kuchmiy; Steven Strubbe; Matthew A Lawlor; Victoria da Silva-Diz; Shirley Luo; Stéphanie Gachet; Carlos A García-Prieto; Rico Hagelaar; Manel Esteller; Jules P P Meijerink; Jean Soulier; Tom Taghon; Pieter Van Vlierberghe; Charles G Mullighan; Hossein Khiabanian; Pedro P Rocha; Daniel Herranz
Journal:  Blood Cancer Discov       Date:  2020-11-24

4.  Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer.

Authors:  Bodo C Melnik
Journal:  Nutr Metab (Lond)       Date:  2017-08-15       Impact factor: 4.169

Review 5.  Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.

Authors:  Eileen M McGowan; Yiguang Lin; Diana Hatoum
Journal:  Cancers (Basel)       Date:  2018-05-31       Impact factor: 6.639

Review 6.  p53: key conductor of all anti-acne therapies.

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2017-09-19       Impact factor: 5.531

Review 7.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

8.  Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma.

Authors:  Shu-De Feng; Ziming Mao; Chunying Liu; Yu-Song Nie; Bin Sun; Minggao Guo; Changqing Su
Journal:  Onco Targets Ther       Date:  2017-11-23       Impact factor: 4.147

9.  Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Authors:  Margaret Pain; Huaien Wang; Eunjee Lee; Maya Strahl; Wissam Hamou; Robert Sebra; Jun Zhu; Raymund L Yong
Journal:  Oncotarget       Date:  2017-12-20

10.  XAF1 as a modifier of p53 function and cancer susceptibility.

Authors:  Emilia M Pinto; Bonald C Figueiredo; Wenan Chen; Henrique C R Galvao; Maria Nirvana Formiga; Maria Candida B V Fragoso; Patricia Ashton-Prolla; Enilze M S F Ribeiro; Gabriela Felix; Tatiana E B Costa; Sharon A Savage; Meredith Yeager; Edenir I Palmero; Sahlua Volc; Hector Salvador; Jose Luis Fuster-Soler; Cinzia Lavarino; Guillermo Chantada; Dominique Vaur; Vicente Odone-Filho; Laurence Brugières; Tobias Else; Elena M Stoffel; Kara N Maxwell; Maria Isabel Achatz; Luis Kowalski; Kelvin C de Andrade; Alberto Pappo; Eric Letouze; Ana Claudia Latronico; Berenice B Mendonca; Madson Q Almeida; Vania B Brondani; Camila M Bittar; Emerson W S Soares; Carolina Mathias; Cintia R N Ramos; Moara Machado; Weiyin Zhou; Kristine Jones; Aurelie Vogt; Payal P Klincha; Karina M Santiago; Heloisa Komechen; Mariana M Paraizo; Ivy Z S Parise; Kayla V Hamilton; Jinling Wang; Evadnie Rampersaud; Michael R Clay; Andrew J Murphy; Enzo Lalli; Kim E Nichols; Raul C Ribeiro; Carlos Rodriguez-Galindo; Marta Korbonits; Jinghui Zhang; Mark G Thomas; Jon P Connelly; Shondra Pruett-Miller; Yoan Diekmann; Geoffrey Neale; Gang Wu; Gerard P Zambetti
Journal:  Sci Adv       Date:  2020-06-24       Impact factor: 14.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.